Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes
- PMID: 38418892
- DOI: 10.1038/s41391-024-00797-0
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes
Abstract
Background: Natural killer (NK) cells are non-antigen specific innate immune cells that can be redirected to targets of interest using multiple strategies, although none are currently FDA-approved. We sought to evaluate NK cell infiltration into tumors to develop an improved understanding of which histologies may be most amenable to NK cell-based therapies currently in the developmental pipeline.
Methods: DNA (targeted/whole-exome) and RNA (whole-transcriptome) sequencing was performed from tumors from 45 cancer types (N = 90,916 for all cancers and N = 3365 for prostate cancer) submitted to Caris Life Sciences. NK cell fractions and immune deconvolution were inferred from RNA-seq data using quanTIseq. Real-world overall survival (OS) and treatment status was determined and Kaplan-Meier estimates were calculated. Statistical significance was determined using X2 and Mann-Whitney U tests, with corrections for multiple comparisons where appropriate.
Results: In both a pan-tumor and prostate cancer (PCa) -specific setting, we demonstrated that NK cells represent a substantial proportion of the total cellular infiltrate (median range 2-9% for all tumors). Higher NK cell infiltration was associated with improved OS in 28 of 45 cancer types, including (PCa). NK cell infiltration was negatively correlated with common driver mutations and androgen receptor variants (AR-V7) in primary prostate biopsies, while positively correlated with negative immune regulators. Higher levels of NK cell infiltration were associated with patterns consistent with a compensatory anti-inflammatory response.
Conclusions: Using the largest available dataset to date, we demonstrated that NK cells infiltrate a broad range of tumors, including both primary and metastatic PCa. NK cell infiltration is associated with improved PCa patient outcomes. This study demonstrates that NK cells are capable of trafficking to both primary and metastatic PCa and are a viable option for immunotherapy approaches moving forward. Future development of strategies to enhance tumor-infiltrating NK cell-mediated cytolytic activity and activation while limiting inhibitory pathways will be key.
© 2024. The Author(s).
Similar articles
-
Epigenetic modulation and prostate cancer: Paving the way for NK cell anti-tumor immunity.Front Immunol. 2023 Apr 5;14:1152572. doi: 10.3389/fimmu.2023.1152572. eCollection 2023. Front Immunol. 2023. PMID: 37090711 Free PMC article. Review.
-
Transcriptome Analysis of Tumor-Infiltrating Lymphocytes Identifies NK Cell Gene Signatures Associated With Lymphocyte Infiltration and Survival in Soft Tissue Sarcomas.Front Immunol. 2022 Jul 7;13:893177. doi: 10.3389/fimmu.2022.893177. eCollection 2022. Front Immunol. 2022. PMID: 35874727 Free PMC article.
-
Could Harnessing Natural Killer Cell Activity Be a Promising Therapy for Prostate Cancer?Crit Rev Immunol. 2021;41(2):101-106. doi: 10.1615/CritRevImmunol.2021037614. Crit Rev Immunol. 2021. PMID: 34348004 Free PMC article. Review.
-
Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.JAMA Netw Open. 2019 Sep 4;2(9):e199292. doi: 10.1001/jamanetworkopen.2019.9292. JAMA Netw Open. 2019. PMID: 31483464 Free PMC article.
-
A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients.Cancer Immunol Res. 2019 Jul;7(7):1162-1174. doi: 10.1158/2326-6066.CIR-18-0500. Epub 2019 May 14. Cancer Immunol Res. 2019. PMID: 31088844
References
-
- Antonarakis ES, Park SH, Goh JC, Shin SJ, Lee JL, Mehra N, et al. Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial. J Clin Oncol. 2023;41:3839. - PubMed - PMC - DOI
Grants and funding
- T32 GM008244/GM/NIGMS NIH HHS/United States
- R35 CA283892/CA/NCI NIH HHS/United States
- P01 CA111412/CA/NCI NIH HHS/United States
- P30 CA077598/CA/NCI NIH HHS/United States
- P01 CA065493/CA/NCI NIH HHS/United States
- T32 GM008244/GM/NIGMS NIH HHS/United States
- T32 GM008244/GM/NIGMS NIH HHS/United States
- R35 CA283892/CA/NCI NIH HHS/United States
- P01 CA111412/CA/NCI NIH HHS/United States
- P30 CA077598/CA/NCI NIH HHS/United States
- P01 CA111412/CA/NCI NIH HHS/United States
- P01 CA065493/CA/NCI NIH HHS/United States
- R35 CA283892/CA/NCI NIH HHS/United States
- P01 CA065493/CA/NCI NIH HHS/United States
- P01 CA111412/CA/NCI NIH HHS/United States
- P30 CA077598/CA/NCI NIH HHS/United States
- P30 CA077598/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Research Materials